1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support
3. Executive Summary
3.1. Outlook in the Parkinson's Disease Therapeutics Market
3.2. Opportunities in the Parkinson's Disease Therapeutics Market
4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter's Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
5. Global Parkinson's Disease Therapeutics Market, by Drug Class
5.1. Overview
5.2. Market Sizing & Forecasting
5.3. Anticholinergics
5.4. COMT Inhibitors
5.5. Carbidopa/Levodopa
5.6. Dopamine Receptor Agonists
5.7. Mao Inhibitors
6. Global Parkinson's Disease Therapeutics Market, by Distribution Channel
6.1. Overview
6.2. Market Sizing & Forecasting
6.3. Hospital Pharmacies
6.4. Online Pharmacies
6.5. Retailer Pharmacies
7. Global Parkinson's Disease Therapeutics Market, by End User
7.1. Overview
7.2. Market Sizing & Forecasting
7.3. Clinics
7.4. Hospitals
8. Global Parkinson's Disease Therapeutics Market, by Geography
8.1. Overview
8.2. Market Sizing & Forecasting
8.3. Americas
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. Argentina
8.3.4. Brazil
8.3.5. Canada
8.3.6. Mexico
8.3.7. United States
8.4. Asia-Pacific
8.4.1. Overview
8.4.2. Market Sizing & Forecasting
8.4.3. Australia
8.4.4. China
8.4.5. India
8.4.6. Japan
8.5. Europe, Middle East & Africa
8.5.1. Overview
8.5.2. Market Sizing & Forecasting
8.5.3. France
8.5.4. Germany
8.5.5. Italy
8.5.6. Spain
8.5.7. United Kingdom
9. Competitive Landscape
9.1. 360iResearch FPNV Positioning Matrix for Global Parkinson's Disease Therapeutics Market
9.2. Market Vendor Ranking Analysis for Global Parkinson's Disease Therapeutics Market
9.3. Competitive News Feed Analysis for Global Parkinson's Disease Therapeutics Market
10. Company Usability Profiles
10.1. Boehringer Ingelheim
10.1.1. Overview
10.1.2. Strategy
10.1.3. SWOT
10.2. GSK
10.2.1. Overview
10.2.2. Strategy
10.2.3. SWOT
10.3. Merck
10.3.1. Overview
10.3.2. Strategy
10.3.3. SWOT
10.4. Novartis
10.4.1. Overview
10.4.2. Strategy
10.4.3. SWOT
10.5. Teva
10.5.1. Overview
10.5.2. Strategy
10.5.3. SWOT
10.6. Abbvie
10.7. Impax
10.8. Lundbeck
10.9. Sun Pharma
10.10. Valeant Pharmaceuticals
11. Appendix
11.1. Discussion Guide
11.2. Top Reports
11.2.1. Global Crane Rental Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.2. Global Computer Vision Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.3. Global Payment Gateway Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.4. Global B2B Travel Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.5. Global Varicose Vein Treatment Devices Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.3. Author Details